Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement